REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2014

Dec 18, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2014-12-16

Reporting Person: STAHL NEIL (SVP Research and Development S)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-12-16	Common Stock	M	3264.0	$30.63	Acquired	6541	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-12-16	Incentive Stock Option (right to buy)	$30.63	M	3264.0	Disposed	2020-12-14	Common Stock (3264)	Direct
2014-12-16	Non-Qualified Stock Option (right to buy)	$52.03	A	75000.0	Acquired	2021-12-16	Common Stock (75000)	Direct
2014-12-16	Non-Qualified Stock Option (right to buy)	$399.66	A	80750.0	Acquired	2024-12-16	Common Stock (80750)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	20000	Indirect
Common Stock	10864	Indirect
Common Stock	5568	Indirect
Common Stock	10000	Indirect

Footnotes

F1: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

F2: On December 16, 2011, the reporting person was granted an option to purchase 75,000 shares of Common Stock. The option vests, partially or in full, on December 31, 2014, based on the extent to which the company satisfies certain performance criteria during the period ending December 31, 2014. The performance criteria have been met and the option will vest as to all 75,000 shares on December 31, 2014.

F3: The stock option award vests in four equal annual installments, commencing one year after the date of grant.